Christine Berni Silverstein - 15 Jun 2026 Form 4 Insider Report for ABEONA THERAPEUTICS INC. (ABEO)

Reporting relationship: Director
Issuer ticker: ABEO
Reported as of: 15 Jun 2026
Net transaction value: -$103,695
SEC form: 4
Accepted by SEC: 15 Jun 2026, 19:48:40 UTC
Prior SEC filing: 04 Feb 2026
Source filing: View source filing
Reporting owner signature: /s/ Christine Silverstein

Key filing fact

Christine Berni Silverstein filed Form 4 for ABEONA THERAPEUTICS INC. (ABEO) on 15 Jun 2026.

Key facts

This page summarizes Christine Berni Silverstein's Form 4 filing for ABEONA THERAPEUTICS INC. (ABEO).
1 reported transaction and 0 derivative rows are listed below.
Accepted by SEC: 15 Jun 2026, 19:48.

Change

Previous filing in this sequence was filed on 04 Feb 2026.
Current net transaction value: -$103,695.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001772546 Primary reporting owner

Silverstein Christine Berni

Relationship: Director
Address: 6555 CARNEGIE AVE., 4TH FLOOR, CLEVELAND
Signature: /s/ Christine Silverstein
Signature date: 15 Jun 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

ABEO transaction

Common Stock

Sale

Transaction value: $103,695
Shares: -18,160
Change %: -13%
Price: $5.71
Shares after: 119,562
Date: 15 Jun 2026
Ownership: Direct
Footnotes: F1, F2

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Section 16 status

Christine Berni Silverstein is no longer subject to Section 16 filing requirements. Form 4 or Form 5 obligations may still apply in specific circumstances.

Explanation of responses 2 footnotes

Footnote F1

The sale reported in this Form 4 was to cover tax obligations associated with the vesting of restricted stock awards.

Footnote F2

The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $5.68 to $5.73 inclusive. The reporting person undertakes to provide the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above.